Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$128.77 USD

128.77
1,236,000

+1.38 (1.08%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $128.69 -0.08 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.

What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?

by Zacks Equity Research

On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.

Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.

Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the first quarter of 2024 in both the United States and International segments.

Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.

Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect

by Zacks Equity Research

Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.

GSK Gears Up for Q1 Earnings: Here's What to Expect

by Zacks Equity Research

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.

Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.

AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.

Henry Schein (HSIC) Gears Up for Q1 Earnings: Factors to Note

by Zacks Equity Research

Henry Schein's (HSIC) first-quarter 2024 results are likely to indicate a strong sales recovery post last year's cybersecurity incident.

Viking (VKTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCB

Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCG

REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study

by Zacks Equity Research

Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.

Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.

Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.

Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT)

by Zacks Equity Research

Sarepta Therapeutics (SRPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on Avalo Therapeutics' (AVTX) lead pipeline drug when it reports fourth-quarter earnings results.

Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.